Comparative Pharmacology
Head-to-head clinical analysis: CLOPRA YELLOW versus PROMETHAZINE VC PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOPRA YELLOW versus PROMETHAZINE VC PLAIN.
CLOPRA-"YELLOW" vs PROMETHAZINE VC PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clopra (metoclopramide) is a dopamine D2 receptor antagonist and, at higher doses, a serotonin 5-HT4 receptor agonist, which enhances gastrointestinal motility and accelerates gastric emptying. It also has central antiemetic effects via D2 blockade in the chemoreceptor trigger zone.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), sedative, antiemetic, and anticholinergic effects. Phenylephrine is a sympathomimetic amine acting primarily on alpha-1 adrenergic receptors, causing vasoconstriction.
Adult: 25-50 mg orally 3-4 times daily; maximum 200 mg/day. For severe pain: 50-100 mg intramuscularly every 4-6 hours; maximum 300 mg/day.
Adults: 1 tablet (promethazine 6.25 mg, phenylephrine 10 mg) orally every 4-6 hours as needed, not to exceed 4 tablets in 24 hours.
None Documented
None Documented
8-12 hours in normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is approximately 9–16 hours (mean ~12 hours) in adults; may be prolonged in hepatic impairment or elderly patients.
Renal: 70% unchanged, Biliary/Fecal: 20% as metabolites, 10% other
Primarily renal as inactive metabolites; approximately 70-80% excreted in urine, with about 20-30% in feces via biliary secretion. Less than 1% excreted unchanged.
Category C
Category A/B
Antiemetic/Prokinetic Agent
Antihistamine / Antiemetic